Edition:
India

Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

131.36USD
16 Aug 2019
Change (% chg)

$0.82 (+0.63%)
Prev Close
$130.54
Open
$131.61
Day's High
$131.65
Day's Low
$130.61
Volume
1,792,996
Avg. Vol
2,050,461
52-wk High
$148.97
52-wk Low
$122.00

Select another date:

Tue, Aug 6 2019

UPDATE 1-GSK ends development of Ebola vaccine, hands work to U.S. institute

LONDON, Aug 6 British drugmaker GlaxoSmithKline is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

Oklahoma makes final bid to hold J&J responsible for opioid epidemic

Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

Oklahoma makes final bid to hold J&J responsible for opioid epidemic

Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fuelling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

REFILE-Oklahoma makes final bid to hold J&J responsible for opioid epidemic

July 31 Oklahoma's attorney general on Wednesday made his final bid to force Johnson & Johnson to pay $17 billion for its part in fueling the opioid epidemic, saying the drugmaker's "egregious" marketing caused an oversupply of addictive drugs and overdose deaths.

J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

UPDATE 2-J&J says FTC probing efforts to protect arthritis drug Remicade

WASHINGTON, July 29 The Federal Trade Commission issued civil subpoenas to Johnson and Johnson in June as part of an investigation into whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

J&J warns of hit from generic drugs in third quarter, shares fall

Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

UPDATE 3-J&J warns of hit from generic drugs in third quarter, shares fall

July 16 Johnson & Johnson on Tuesday boosted its 2019 sales forecast amid robust demand for its cancer drugs, but warned that competition from generic and copycat drugs could impact its third-quarter results, sending shares down 1.4% in noon trading.

Johnson & Johnson quarterly profit jumps 41.8%

July 16 Johnson & Johnson reported a 41.8% rise in second-quarter profit on Tuesday, helped by its pharmaceuticals business.

Select another date: